Private Advisor Group LLC Increases Stake in DexCom, Inc. (NASDAQ:DXCM)

Private Advisor Group LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM) by 9.1% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 10,710 shares of the medical device company’s stock after buying an additional 891 shares during the quarter. Private Advisor Group LLC’s holdings in DexCom were worth $1,214,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DXCM. Vanguard Group Inc. lifted its stake in DexCom by 0.3% during the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after purchasing an additional 136,282 shares during the last quarter. Capital Research Global Investors lifted its stake in DexCom by 21.4% during the fourth quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares during the last quarter. Sands Capital Management LLC lifted its stake in DexCom by 10.2% during the fourth quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Capital World Investors lifted its stake in DexCom by 130.7% during the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock worth $1,151,392,000 after purchasing an additional 5,256,092 shares during the last quarter. Finally, Artisan Partners Limited Partnership lifted its stake in DexCom by 164.8% during the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock worth $732,169,000 after purchasing an additional 3,672,471 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on DXCM shares. Robert W. Baird increased their price objective on DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a report on Monday, August 5th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. JPMorgan Chase & Co. cut shares of DexCom from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $145.00 to $75.00 in a report on Friday, July 26th. Oppenheimer lowered their price target on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, July 26th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $145.00 price objective on shares of DexCom in a research note on Tuesday, July 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Trading Up 1.0 %

Shares of DXCM stock opened at $69.51 on Monday. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48. The business’s fifty day moving average price is $82.36 and its 200 day moving average price is $111.23. The firm has a market capitalization of $27.85 billion, a PE ratio of 44.85, a P/E/G ratio of 2.12 and a beta of 1.18.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The business’s revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm posted $0.34 EPS. As a group, sell-side analysts forecast that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Insider Activity

In other news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares in the company, valued at approximately $5,217,436.65. The disclosure for this sale can be found here. In the last three months, insiders sold 2,483 shares of company stock worth $201,708. Company insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.